- Home
- CTW vs TLSA Comparison
CTW vs TLSA Comparison
Compare CTW & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTW | TLSA |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | Japan | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.0M | 145.1M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CTW | TLSA |
|---|---|---|
| Price | $1.75 | $0.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.02 |
| AVG Volume (30 Days) | 13.8K | ★ 552.7K |
| Earning Date | 10-15-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $0.76 |
| 52 Week High | $3.14 | $2.10 |
Technical Indicators
Market Signals| Indicator | CTW | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 37.28 | 41.72 |
| Support Level | $1.19 | $0.90 |
| Resistance Level | $1.88 | $1.17 |
| Average True Range (ATR) | 0.32 | 0.07 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 5.48 | 10.46 |
Price Performance
Historical ComparisonAbout CTW CTW Cayman Class A Ordinary Shares
CTW operates as a gaming platform company providing instant access to free-to-play, browser-based games inspired by popular Japanese animation, including "So I'm a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World's Strongest - Rebellion Soul", and "Queen's Blade Limit Break". CTW delivers these games through its flagship HTML5 platform, G123.jp.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.